EHA 2015 | A review of the treatment evolution in relapsed/refractory multiple myeloma
Paul Richardson
• 12 Jun 2015
Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses his highlights of the 20th Congress of the European Hematology Association (EHA). A substantial number of new agents, including monoclonal antibodies, and emerging drug classes in clinical development have shown promising activity for the treatment of multiple myeloma.
